Dr. Nathan C. Tidwell
Claim this profileEisenhower Army Medical Center
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
2 reported clinical trials
4 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
Stage IV
MET positive
KRAS positive
2Lung Cancer
Stage IV
MET positive
KRAS positive
Affiliated Hospitals
Clinical Trials Nathan C. Tidwell is currently running
Symptom Monitoring
for Young Women on Hormone Therapy
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines.
Recruiting1 award N/A13 criteria
Ramucirumab + Pembrolizumab vs Chemotherapy
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.
Recruiting2 awards Phase 310 criteria
More about Nathan C. Tidwell
Clinical Trial Related1 year of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Nathan C. Tidwell has experience with
- Chemotherapy
- Pembrolizumab
- Ramucirumab
- Hormone Therapy
Breakdown of trials Nathan C. Tidwell has run
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nathan C. Tidwell specialize in?
Nathan C. Tidwell focuses on Non-Small Cell Lung Cancer and Lung Cancer. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are MET positive.
Is Nathan C. Tidwell currently recruiting for clinical trials?
Yes, Nathan C. Tidwell is currently recruiting for 2 clinical trials in Fort Gordon Georgia. If you're interested in participating, you should apply.
Are there any treatments that Nathan C. Tidwell has studied deeply?
Yes, Nathan C. Tidwell has studied treatments such as Chemotherapy, Pembrolizumab, Ramucirumab.
What is the best way to schedule an appointment with Nathan C. Tidwell?
Apply for one of the trials that Nathan C. Tidwell is conducting.
What is the office address of Nathan C. Tidwell?
The office of Nathan C. Tidwell is located at: Eisenhower Army Medical Center, Fort Gordon, Georgia 30905-5650 United States. This is the address for their practice at the Eisenhower Army Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.